Eisai's Groundbreaking Dementia Drug Set To Transform Treatment In America
Eisai aims to commercialize a tau-targeting dementia drug by 2030, following Leqembi's success.
Japanese pharmaceutical company Eisai is working on a new dementia treatment, aiming for U.S. commercialization by fiscal 2030, according to a Sunday report by the Nikkei. The drug targets the tau protein, which is responsible for Alzheimer's disease symptoms. Eisai already markets a dementia drug in the U.S. called Leqembi, developed in collaboration with American partner Biogen. On Friday, the companies announced plans to launch Leqembi in China, making it the third country to offer the treatment after the U.S. and Japan.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion